With more specialty medicines coming to market, the care coordination and financial management associated with high-value therapies is increasing in complexity.
There has been growing criticism of “vaccine inequality” as developing countries struggle to secure supplies while wealthy nations begin inoculating populations.
A lot of people are surviving cancer because new treatments are so effective. But there's one thing that stands in the way for many people, and that's having the money to pay for the drugs to fight their cancer.
Macroeconomic pressures have hit the R&D returns of life sciences firms.